US 11,787,872 B2
Methods and compositions related to antibody fragments that bind to tumor-associated glycoprotein 72 (TAG-72)
Thomas J. Magliery, Columbus, OH (US); Brandon J. Sullivan, Gahanna, OH (US); and Nicholas E. Long, Columbus, OH (US)
Assigned to Ohio State Innovation Foundation, Columbus, OH (US)
Filed by OHIO STATE INNOVATION FOUNDATION, Columbus, OH (US)
Filed on Nov. 25, 2019, as Appl. No. 16/694,052.
Application 16/694,052 is a continuation of application No. 15/328,222, granted, now 10,487,151, previously published as PCT/US2015/041809, filed on Jul. 23, 2015.
Claims priority of provisional application 62/028,003, filed on Jul. 23, 2014.
Prior Publication US 2020/0255538 A1, Aug. 13, 2020
This patent is subject to a terminal disclaimer.
Int. Cl. C07K 16/30 (2006.01); A61K 51/10 (2006.01); A61K 39/395 (2006.01); G01N 33/574 (2006.01); A61K 47/60 (2017.01); A61K 39/00 (2006.01)
CPC C07K 16/3092 (2013.01) [A61K 39/39558 (2013.01); A61K 39/39591 (2013.01); A61K 47/60 (2017.08); A61K 51/1045 (2013.01); A61K 51/1093 (2013.01); G01N 33/57492 (2013.01); A61K 2039/505 (2013.01); C07K 2317/14 (2013.01); C07K 2317/24 (2013.01); C07K 2317/622 (2013.01); C07K 2317/76 (2013.01); C07K 2317/92 (2013.01); C07K 2317/94 (2013.01); G01N 2333/4728 (2013.01)] 10 Claims
 
1. A method for in vitro immunodetection of TAG-72-expressing cancer cells comprising a step of contacting the cancer cells with an antibody fragment which specifically binds tumor-associated glycoprotein 72 (TAG-72), wherein the antibody fragment comprises an amino acid sequence with 98% or more identity to SEQ ID NO: 13, 33, 35, 37, 39, 41, 43, or 45, wherein said antibody fragment comprises complementarity determining regions (CDRs), wherein said CDRs comprise amino acid residues 53-57, 72-88, 122-126, 166-182, 198-204, and 237-245 of SEQ ID NO: 13; residues 76-80, 95-111, 144-149, 189-205, 221-227, and 260-268 of SEQ ID NO: 33; residues 76-80, 95-111, 144-149, 209-225, 241-247, and 280-288 of SEQ ID NO: 35; residues 76-80, 95-111, 144-149, 204-220, 236-242, and 275-283 of SEQ ID NO: 37; residues 76-80, 95-111, 144-149, 199-215, 231-237, and 270-278 of SEQ ID NO: 39; residues 76-80, 95-111, 144-149, 188-204, 220-226, and 259-267 of SEQ ID NO: 41; residues 76-80, 95-111, 144-149, 188-204, 220-226, and 259-267 of SEQ ID NO: 43; and residues 76-80, 95-111, 144-149, 189-205, 221-227, and 260-268 of SEQ ID NO: 45; or wherein the antibody fragment comprises SEQ ID NOS: 15, 17, 19, 21, 23, 25, 27, 29, or 31.